Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Osborne CK, et al. J Clin Oncol. 2002 Aug 15;20(16):3386-95. doi: 10.1200/JCO.2002.10.058. J Clin Oncol. 2002. PMID: 12177098 Clinical Trial.
Prognostic factors in breast cancer.
Elledge RM, McGuire WL, Osborne CK. Elledge RM, et al. Among authors: osborne ck. Semin Oncol. 1992 Jun;19(3):244-53. Semin Oncol. 1992. PMID: 1351692 Review. No abstract available.
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK. Rivkin SE, et al. Among authors: osborne ck. J Clin Oncol. 1994 Oct;12(10):2078-85. doi: 10.1200/JCO.1994.12.10.2078. J Clin Oncol. 1994. PMID: 7931477 Clinical Trial.
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Russell CA, et al. Among authors: osborne ck. J Clin Oncol. 1997 Jul;15(7):2494-501. doi: 10.1200/JCO.1997.15.7.2494. J Clin Oncol. 1997. PMID: 9215817 Clinical Trial.
372 results